AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 71 min read$CGEM

Michaelson Jennifer sold $143K of CGEM

Michaelson Jennifer (Chief Scientific Officer) sold 8,000 shares of Cullinan Therapeutics, Inc. (CGEM) at $17.82 ($0.14M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Michaelson Jennifer
Published Jul 7, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CGEM
Neutral
high confidence
Mentioned
$CGEM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGEMNeutralLow
01

Why it matters

The disclosed sale is not accompanied by any new company-specific news (no guidance, trial results, deals, or regulatory actions).

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a fundamental repricing.

03

What to watch

The article lacks context on total compensation, prior sale cadence, and whether the plan is part of scheduled diversification; those factors can reduce interpretability.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-07 after-hours; reflects 2026-07-06 sale details.

Background

The article is a primary-source SEC Form 4 insider transaction for Cullinan Therapeutics, Inc. (CGEM).

Company-level read

Ticker impact

$CGEMNeutralHigh confidence
Context

Cullinan Therapeutics insider Form 4 shows CSO Jennifer Michaelson sold 8,000 shares at $17.8200 on 2026-07-06 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and sentiment-driven.

Evidence & confidence

The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.

Market effects

Sector

No sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still be interpreted as confidence erosion by some traders.

Key entities

  • issuer
    Cullinan Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CSO sale disclosed under a 10b5-1 plan.

  • insider
    Jennifer Michaelson

    Chief Scientific Officer who sold 8,000 shares at $17.8200 on 2026-07-06.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CGEM insider trading history →

Related articles

OCT 2
MedAI 8/10

Cullinan Therapeutics starts zipalertinib NDA submission

Cullinan Therapeutics (CGEM) began submitting an NDA for zipalertinib in combination with chemotherapy for first-line lung cancer under FDA's real-time review program. The Phase 3 trial showed median progression-free survival of 14.5 months for the combination vs. 8.5 months for chemotherapy alone. Cullinan expects to complete the submission by year-end 2026. Shares closed at $14.53, down 5.34%.

mugglehead.com2 min
OCT 2
$CGEMMedAI 8/10

H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing

H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (CGEM) after its rolling NDA submission for zipalertinib. The stock is up 153% over a year, trading at $14.53. Positive Phase 3 trial results showed improved outcomes for zipalertinib plus chemotherapy in NSCLC. Approval could trigger milestone payments. CGEM has strong cash position but high annual burn rate.

investing.com3 min